The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (TNBC) patients.
The main questions it aims to answer are:
* What are the senescent features of peripheral T lymphocytes in young TNBC patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy? * What is the relationship between senescent T cells and adverse events, DFS and tumor infiltrating lymphocytes?
1. Participants will receive 6 cycles of docetaxel + adriamycin/epirubicin + cyclophosphamide (TEC/TAC) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy.
2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.
3.Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
Female, age≤40 years old,
Invasive breast cancer confirmed by pathology, immunohistochemistry showed TNBC (ER-, PR-, HER2-),
Indications for neoadjuvant chemotherapy according to guidelines: tumor diameter > 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy.
Stage IV patients or a history of other malignancies,
Having microbial infection or autoimmune disease have not been cured or having HBV, HIV infection,
Having surgery 3 months before enrollment,
Patients with insufficient clinicopathological data,
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead sponsor